교수진 소개
- Name
- Koo, Ha Rim, Ph.D.
- Faculty Appointment
(title, department)
- Department of Cancer Biomedical Science Graduate School of Cancer Science and Policy
- Area of Expertise
- Bioinformatics & Cancer Genomics
- E-mail
- harimkoo@ncc.re.kr
- Work Experience
-
Postdoctoral Researcher, Cancer Genomics Lab, Korea University College of Medicine
Postdoctoral Researcher, Cancer Proteogenomic Analysis Consortium, National Cancer Center
Senior Scientist, AI Precision Medicine Team, AIMED BIO INC
Researcher, Proteomics Core Facility, Research Core Center, Research Institute National Cancer Center
Researcher, Institute for Refractory Cancer Research, Samsung Medical Center
- Educational Background
- Ph.D. in Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology Sungkyunkwan University, Seoul, Korea
B.S. in Applied Chemical Engineering (Chemical Engineering Major), Computer Engineering (Software Engineering Minor),
Chonnam National University, Gwangju, Korea
- Research Interests
- Dr. Koo previous research interests involved exploring and identifying multi-omics-based biomarkers for glioblastoma and its molecular diversification based on racial populations. In the NCC, Dr. Koo is currently analyzing the evolutionary dynamics of longitudinal cancer patients based on their treatment response for addressing precision oncology treatment.
- International Collaboration
- Glioma TMZ Prediction, HKUST, Hong Kong
Multi-omics Longitudinal GBM, University of Miami Miller School of Medicine, USA
- Achievements
-
(2023) Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild type primary glioblastoma, Accepted, (IF=15.266), Genome Med
(2021) Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma, PMID:33828082, (IF=9.696), Cell Death Dis
(2021) Modulation of Nogo receptor 1 expression orchestrates myelin-associated infiltration of glioblastoma, PMID:33479772, (IF=15.255), Brain
(2020) Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts, PMID:33142709, (IF=6.575), Cancers (Basel)
(2020) Ethnic delineation of primary glioblastoma genome, PMID:32794373, (IF=4.711), Cancer Med
(2020) Multi-Habitat Radiomics Unravels Distinct Phenotypic Subtypes of Glioblastoma with Clinical and Genomic Significance, PMID:32605068, (IF=6.575), Cancers (Basel)
(2020) Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening, PMID:32120790, (IF=6.575), Cancers (Basel)
(2020) Comprehensive pharmacogenomic characterization of gastric cancer, PMID:32070411, (IF=15.266), Genome Med
(2019) Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers, PMID:31771620, (IF=18.01), Genome Biol
(2019) Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models, PMID:31370279, (IF=6.575), Cancers (Basel)
(2020) Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas, PMID:31096737, (IF=5.036), Cancer Res Treat
(2019) Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with RUNX1-RUNX1T1 Fusion, PMID:30959925, (IF=6.208), Int J Mol Sci
(2019) Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation, PMID:30759398, (IF=9.995), Cell Rep
(2019) Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma, PMID:29939324, (IF=13.029), Neuro Oncol
